Brought to you by 
Magenta Therapeutics closes $50mm Series B round
03 May 2017
Executive Summary
Magenta Therapeutics Inc. (curative stem cell transplantation) raised $50mm through an oversubscribed Series B round from GV (lead; formerly Google Ventures) and all existing investors including Atlas Venture, Third Rock Ventures, Partners Innovation Fund, Access Industries, Casdin Capital, Be The Match BioTherapies, and undisclosed crossover investors. The company also announced an in-licensing from Novartis AG, and a partnership with Be The Match BioTherapies, a division of bone marrow and umbilical cord transplantation organization National Marrow Donor Program/Be The Match.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Magenta Therapeutics closes $50mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice